Evidence map›Paper›PMID 42211057›Full record

ArticleMaterials today. Bio2026

Cardiac-homing peptide-targeted colchicine-based drugstores with inhibiting inflammatory response for myocardial infarction improvement.

Xing Zhang, Wenhua Xu, Jie Song, Huanhuan Ding, Shujie Yu, Nan Yang, Dilare Taiwaikuli, Yemin Chen, Yanmei Lu, Baopeng Tang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xing ZhangDepartment of Cardiac Pacing and Electrophysiology, Xinjiang Key Laboratory of Cardiac Electrophysiology and Remodeling, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830054, China.
Wenhua XuDepartment of Cardiology, Changji Prefecture People's Hospital in Xinjiang Uygur Autonomous Region, No.303 Yan'an Road, Changji City, Xinjiang, 831100, China.
Jie SongDepartment of Cardiac Pacing and Electrophysiology, Xinjiang Key Laboratory of Cardiac Electrophysiology and Remodeling, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830054, China.
Huanhuan DingDepartment of Cardiac Pacing and Electrophysiology, Xinjiang Key Laboratory of Cardiac Electrophysiology and Remodeling, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830054, China.
Shujie YuSchool of Pharmaceutical Sciences, Institute of Materia Medica, Xinjiang University, Urumqi, 830017, China.
Nan YangSchool of Pharmaceutical Sciences, Institute of Materia Medica, Xinjiang University, Urumqi, 830017, China.
Dilare TaiwaikuliDepartment of Cardiac Pacing and Electrophysiology, Xinjiang Key Laboratory of Cardiac Electrophysiology and Remodeling, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830054, China.
Yemin ChenDepartment of Cardiac Pacing and Electrophysiology, Xinjiang Key Laboratory of Cardiac Electrophysiology and Remodeling, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830054, China.
Yanmei LuDepartment of Cardiac Pacing and Electrophysiology, Xinjiang Key Laboratory of Cardiac Electrophysiology and Remodeling, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830054, China.
Baopeng TangDepartment of Cardiac Pacing and Electrophysiology, Xinjiang Key Laboratory of Cardiac Electrophysiology and Remodeling, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830054, China.
Zhongxiong FanSchool of Pharmaceutical Sciences, Institute of Materia Medica, Xinjiang University, Urumqi, 830017, China.
Xianhui ZhouDepartment of Cardiac Pacing and Electrophysiology, Xinjiang Key Laboratory of Cardiac Electrophysiology and Remodeling, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830054, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

One of the primary challenges in addressing cardiac injury is the limited cardiac specificity of therapeutic drugs. Lipid nanoparticles (LNPs) are a relatively novel class of delivery vehicles used for administering RNA and various drugs. A major challenge in the treatment of cardiac injury remains the poor cardiac specificity of most therapeutic agents. Despite their promise as a relatively novel delivery platform for RNA and other payloads, LNPs do not adequately overcome this limitation. Nevertheless, these LNPs exhibited preferential accumulation in the liver rather than the heart. To address this off-target biodistribution and enhance delivery efficiency to cardiac tissue, surface functionalization with cardiac-homing peptides (CHP) was performed. In this study, the CHP-functionalized LNP loaded with colchicine (termed as CCP) was developed as a targeted therapeutic platform for myocardial repair. This novel drug delivery system successfully localizes to the ischemic myocardium and precisely releases CCP to hypoxic, mildly acidic cardiomyocytes. In conclusion, CCP presents a promising platform for the sustained and localized delivery of drugs to the heart, thereby enhancing the therapeutic efficacy for cardiovascular diseases.

Indexed as

Cardiac-homing peptideColchicineLiposomesMyocardial infarction

Identifiers

PMID42211057
PMCPMC13214554

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.